首页> 美国卫生研究院文献>Frontiers in Pediatrics >Plasma Biomarker Analysis in Pediatric ARDS: Generating Future Framework from a Pilot Randomized Control Trial of Methylprednisolone: A Framework for Identifying Plasma Biomarkers Related to Clinical Outcomes in Pediatric ARDS
【2h】

Plasma Biomarker Analysis in Pediatric ARDS: Generating Future Framework from a Pilot Randomized Control Trial of Methylprednisolone: A Framework for Identifying Plasma Biomarkers Related to Clinical Outcomes in Pediatric ARDS

机译:儿科ARDS中的血浆生物标志物分析:从甲基强的松龙的随机对照试验中产生未来的框架:识别与儿科ARDS的临床结果相关的血浆生物标志物的框架

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectiveLung injury activates multiple pro-inflammatory pathways, including neutrophils, epithelial, and endothelial injury, and coagulation factors leading to acute respiratory distress syndrome (ARDS). Low-dose methylprednisolone therapy (MPT) improved oxygenation and ventilation in early pediatric ARDS without altering duration of mechanical ventilation or mortality. We evaluated the effects of MPT on biomarkers of endothelial [Ang-2 and soluble intercellular adhesion molecule-1 (sICAM-1)] or epithelial [soluble receptor for activated glycation end products (sRAGE)] injury, neutrophil activation [matrix metalloproteinase-8 (MMP-8)], and coagulation (plasminogen activator inhibitor-1).
机译:目的肺损伤可激活多种促炎途径,包括中性粒细胞,上皮和内皮损伤,以及导致急性呼吸窘迫综合征(ARDS)的凝血因子。小剂量甲基强的松龙疗法(MPT)改善了小儿ARDS的氧合和通气,而没有改变机械通气的持续时间或死亡率。我们评估了MPT对内皮[Ang-2和可溶性细胞间粘附分子-1(sICAM-1)]或上皮[活化糖基化终产物(sRAGE)的可溶性受体]损伤,中性粒细胞活化[基质金属蛋白酶-8]的生物标志物的影响。 (MMP-8)]和凝血(纤溶酶原激活物抑制剂1)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号